Expert Interview
Examining the Future Use of Abbott's Freestyle Libre CGMs in Diabetes Care Amid Safety and Sensor Concerns
Ticker(s): ABTInstitution: Stanford
- Professor of endocrinology at Stanford
- She is currently a clinician investigator who maintains an active clinic for patients with complicated type 1, type 2, or other forms of diabetes, polycystic ovarian disease, and hypoglcyemia.
- She also conducts studies on the role of incretin hormones in glucose metabolism and postbariatric hypoglycemia, and the use of continuous glucose monitoring and multi-omics methods to define metabolic sub-phenotypes and precision diets for individuals with prediabetes and type 2 diabetes.
How many patients do you provide with CGM?
Added By: lilly_adminOn a scale of 1 to 10, how concerned are you for the FreeStyle Libre 3 & Libre 3 Plus Sensor Correction?
Added By: lilly_adminHow many of your type 1 and 2 diabetic patients utilize a CGM?
Added By: ben_adminWhat are common issues with CGM technologies?
Added By: ben_adminWhat are your thoughts on the recent sensor issues with the FreeStyle Libre?
Added By: ben_adminWill Abbott lose market share because of these sensor issues?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
